Prelude Therapeutics, a Phase 1 biotech developing PRMT5 inhibitors for difficult to treat cancers, raised $158 million by offering 8.3 million shares at $19, the high end of the range of $17 to $19.
The Wilmington, DE-based company plans to list on the Nasdaq under the symbol PRLD. Morgan Stanley, Goldman Sachs and BofA Securities acted as lead managers on the deal.
